Allspring Global Investments Holdings LLC Reduces Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Allspring Global Investments Holdings LLC lowered its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 34.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 181,305 shares of the biotechnology company’s stock after selling 95,226 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.41% of United Therapeutics worth $64,971,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC increased its holdings in United Therapeutics by 176.2% in the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after buying an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares in the last quarter. Comerica Bank raised its holdings in shares of United Therapeutics by 5.9% during the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares in the last quarter. Tri Locum Partners LP purchased a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $15,959,000. Finally, QRG Capital Management Inc. increased its position in shares of United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $370.60 on Tuesday. The stock’s fifty day moving average is $350.66 and its two-hundred day moving average is $309.00. The firm has a market capitalization of $16.49 billion, a P/E ratio of 17.03, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $377.03.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period last year, the firm posted $5.24 EPS. The business’s quarterly revenue was up 19.8% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Co. will post 24.72 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on UTHR shares. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Bank of America lowered their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. UBS Group lifted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $361.33.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $334.00, for a total value of $1,202,400.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $43,420. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $334.00, for a total value of $1,202,400.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $43,420. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at $569,362.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,230 shares of company stock valued at $34,817,406 in the last quarter. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.